What does NaHCO3 treatment potentially lead to in neonates?

The treatment of neonates with sodium bicarbonate (NaHCO3) can potentially lead to intraventricular hemorrhage, particularly in those who are already vulnerable, such as preterm infants or those with other risk factors. Intraventricular hemorrhage is a condition characterized by bleeding into the brain's ventricular system, and the use of NaHCO3 may alter cerebral blood flow, potentially increasing the risk of hemorrhagic events.

Sodium bicarbonate is sometimes used to treat metabolic acidosis, but its administration can cause a rapid rise in serum bicarbonate levels, leading to metabolic alkalosis. This can cause peripheral vasoconstriction, which might reduce cerebral perfusion and compromise the already fragile vasculature in neonates. Therefore, careful consideration is necessary when using this treatment in this population.

The other options do not align with the known risks associated with NaHCO3 treatment in neonates as prominently as intraventricular hemorrhage does. While hypoglycemia, hypernatremia, and sepsis can occur in various clinical situations involving neonates, they are not primary concerns directly linked to sodium bicarbonate therapy in the same way. Thus, intraventricular hemorrhage is the most relevant potential consequence of Na